All Outputs (26)

IL-7 is superior to IL-2 for ex vivo expansion of tumourspecific CD4 + T cells (2009)
Journal Article
Caserta, S., Alessi, P., Basso, V., & Mondino, A. (2010). IL-7 is superior to IL-2 for ex vivo expansion of tumourspecific CD4 + T cells. European journal of immunology, 40(2), 470-479. https://doi.org/10.1002/eji.200939801

It is well established that tumours hinder both natural and vaccine-induced tumourspecific CD4 + T-cell responses. Adoptive T-cell therapy has the potential to circumvent functional tolerance and enhance anti-tumour protective responses. While proto... Read More about IL-7 is superior to IL-2 for ex vivo expansion of tumourspecific CD4 + T cells.

T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance (2009)
Journal Article
Salmond, R. J., Filby, A., Qureshi, I., Caserta, S., & Zamoyska, R. (2009). T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunological reviews, 228(1), 9-22. https://doi.org/10.1111/j.1600-065x.2008.00745.x

T-cell development in the thymus and activation of mature T cells in secondary lymphoid organs requires the ability of cells to respond appropriately to environmental signals at multiple stages of their development. The process of thymocyte selection... Read More about T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance.

Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses (2008)
Journal Article
Caserta, S., Alessi, P., Guarnerio, J., Basso, V., & Mondino, A. (2008). Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses. Cancer Research, 68(8), 3010-3018. https://doi.org/10.1158/0008-5472.can-07-5796

CD4 + helper T cells are critical for protective immune responses and yet suboptimally primed in response to tumors. Cell-based vaccination strategies are under evaluation in clinical trials but limited by the need to derive antigenpresenting cells... Read More about Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses.

Tumors hamper the immunogenic competence of CD4+T cell-directed dendritic cell vaccination (2007)
Journal Article
Zimmermann, V. S., Casati, A., Schiering, C., Caserta, S., Hess Michelini, R., Basso, V., & Mondino, A. (2007). Tumors hamper the immunogenic competence of CD4+T cell-directed dendritic cell vaccination. Journal of Immunology, 179(5), 2899-2909. https://doi.org/10.4049/jimmunol.179.5.2899

Dendritic cells loaded with tumor-derived peptides induce protective CTL responses and are under evaluation in clinical trails. We report in this study that prophylactic administration of dendritic cells loaded with a MHC class II-restricted peptide... Read More about Tumors hamper the immunogenic competence of CD4+T cell-directed dendritic cell vaccination.

Memories are made of this: synergy of T cell receptor and cytokine signals in CD4+ central memory cell survival (2007)
Journal Article
Caserta, S., & Zamoyska, R. (2007). Memories are made of this: synergy of T cell receptor and cytokine signals in CD4+ central memory cell survival. Trends in immunology, 28(6), 245-248. https://doi.org/10.1016/j.it.2007.04.006

The ability of the immune system to 'remember' a previous encounter with antigen is the hallmark of the adaptive immune response. The signals required for CD4 + memory T cell survival are not well understood, and a recent paper lends new biochemical... Read More about Memories are made of this: synergy of T cell receptor and cytokine signals in CD4+ central memory cell survival.

Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk (2005)
Journal Article
Benigni, F., Zimmermann, V. S., Hugues, S., Caserta, S., Basso, V., Rivino, L., Ingulli, E., Malherbe, L., Glaichenhaus, N., & Mondino, A. (2005). Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. Journal of Immunology, 175(2), 739-748. https://doi.org/10.4049/jimmunol.175.2.739

Technical difficulties in tracking endogenous CD4 T lymphocytes have limited the characterization of tumor-specific CD4 T cell responses. Using fluorescent MHC class II/peptide multimers, we defined the fate of endogenous Leishmania receptor for acti... Read More about Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk.